PMC10437098_01
Skin lesion performance of abrocitinib before and after treatment of patients with EPPP. (a) Skin lesions prior to the treatment; (b) Lesion at higher magnification; (c) Significant improvement in the degree of skin lesions after one month of treatment with abrocitinib.
CCID-16-2223-g0001.jpg
PMC10437098_01_CCID-16-2223-g0001.jpg
f0001
These papules exhibited old central atrophy, and they were well-defined, slightly raised, and partially covered with thin scales (Figures 1a and b). After 1-month oral administration of abrocitinib, the skin lesions gradually subsided (Figure 1c).
Pathological presentation of the patient. (HE, x100). The epidermis is mildly hyperplastic, with several keratin-filled depressions showing a tendency to form a conical plate with vacuolated epithelial cells and a partial lack of a granular layer. Lymphocyte infiltration can be seen around dermal vessels (a and b).
CCID-16-2223-g0002.jpg
PMC10437098_01_CCID-16-2223-g0002.jpg
f0002
Moreover, lymphocyte infiltration was observed around dermal vessels (Figures 2a and b).
Questionnaire evaluation of abrocitinib before and after treating patients with EPPP. Pruritus was assessed using the visual analog scale (VAS) and the 12-item pruritus severity scale (12-PSS), and data on quality of life were assessed using the dermal life quality index (DLQI).
CCID-16-2223-g0003.jpg
PMC10437098_01_CCID-16-2223-g0003.jpg
f0003
The subsequent VAS, 12-PSS, and DLQI scores of the patient decreased to 2, 3, and 4, respectively (Figure 3).